Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk <i>Five</i> Study

Details

Request a copyRequest a copy
Serval ID
serval:BIB_8C22A73A1CDB
Type
Inproceedings: an article in a conference proceedings.
Publication sub-type
Abstract (Abstract): shot summary in a article that contain essentials elements presented during a scientific conference, lecture or from a poster.
Collection
Publications
Institution
Production externe
Title
Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk <i>Five</i> Study
Title of the conference
Blood
Author(s)
Yong K., Hinsley S., Auner HW, Sherratt D., De Tute RM, Brown S., Flanagan L., Williams C., Cavenagh J., Kaiser MF, Rabin N., Ramasamy K., Garg M., Hawkins SF, Bygrave C., Morgan GJ, Davies FE, Owen RG
Organization
59th Annual Meeting of the American-Society-of-Hematology (ASH)
Address
Atlanta, United States
ISSN
0006-4971
Publication state
Published
Issued date
07/12/2017
Volume
130
Number
Suppl. 1
Language
english
Web of science
000432419402085
Create date
02/12/2024 17:49
Last modification date
13/12/2024 10:08
Usage data